DNAAF11: A Potential Drug Target for Cancer and Other Diseases

Target Name: DNAAF11

NCBI ID: G23639

DNAAF11

DNAAF11: A Potential Drug Target for Cancer and Other Diseases

DNAAF11 (LRRC6) is a protein that is expressed in various tissues throughout the body. It is a member of the long non-coding RNA (lncRNA) class of genes and is involved in the regulation of cell growth, differentiation, and survival.

Recent studies have identified DNAAF11 as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because DNAAF11 has been shown to play a role in the regulation of cellular processes that are implicated in the development and progression of these diseases.

One of the key mechanisms by which DNAAF11 is thought to contribute to disease development is its role in the regulation of cell-cell adhesion. Adhesion is the process by which cells stick together and form tissues, and it is a critical factor in the development and maintenance of tissues and organs.

Studies have shown that DNAAF11 is involved in the regulation of cell-cell adhesion by promoting the formation of tight junctions, which are specialized structures that mediate the transfer of electrical signals between cells. tight junctions are important for maintaining the integrity of tissues and for ensuring that cells do not come into direct contact with each other, which can cause them to become damaged or unstable.

In addition to its role in cell-cell adhesion, DNAAF11 has also been shown to be involved in the regulation of cell-cell signaling pathways that are important for the development and progression of cancer. For example, studies have shown that DNAAF11 can promote the growth and survival of cancer cells by inhibiting the inhibition of cell proliferation that is caused by various signaling pathways, including the TGF-β pathway.

Another potential mechanism by which DNAAF11 may contribute to disease development is its role in the regulation of stem cell proliferation and differentiation. stem cells are a type of cell that have the ability to develop into any type of cell in the body, and they play a critical role in the development and maintenance of tissues and organs.

Studies have shown that DNAAF11 is involved in the regulation of stem cell proliferation and differentiation by promoting the production of stem cells and by inhibiting the differentiation of stem cells into specialized cells. This may be important for the development of diseases that are characterized by the over-expression of stem cells, such as cancer.

In conclusion, DNAAF11 is a protein that is involved in the regulation of various cellular processes that are important for the development and progression of diseases. Its role in cell-cell adhesion, cell-cell signaling pathways, and stem cell proliferation and differentiation may be important for the development of cancer and other diseases. As such, DNAAF11 is a potential drug target for the treatment of these diseases. Further research is needed to fully understand the role of DNAAF11 in disease development and to develop effective treatments.

Protein Name: Dynein Axonemal Assembly Factor 11

Functions: Involved in dynein arm assembly, is important for expression and transporting outer dynein arm (ODA) proteins from the cytoplasm to the cilia (PubMed:23122589, PubMed:23527195, PubMed:33403504). Acts as a crucial component in the formation and motility of spermatozoal flagella (PubMed:33403504)

The "DNAAF11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAAF11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets